Rapid Dose Therapeutics Full Year 2024 Earnings: CA$0.041 loss per share (vs CA$0.037 loss in FY 2023)

Rapid Dose Therapeutics (CSE:DOSE) Full Year 2024 Results

Key Financial Results

• Revenue: CA$1.02m (up 42% from FY 2023).
• Net loss: CA$4.31m (loss widened by 13% from FY 2023).
• CA$0.041 loss per share (further deteriorated from CA$0.037 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rapid Dose Therapeutics shares are down 12% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Rapid Dose Therapeutics (2 shouldn't be ignored) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com